Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Pozycja w akcjach #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Cena akcji
$1.73
Ostatnia synchronizacja: 2025-06-17
Kapitalizacja rynkowa
$2.55M
Zmiana (1 dzień)
-0.29%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Eiger BioPharmaceuticals, Inc. (EIGR)

Kategoria

Historia ceny akcji dla Eiger BioPharmaceuticals, Inc. (EIGR)
Najwyższa cena zamknięcia: $1.73 dnia 2025-06-01

Najniższa cena zamknięcia: $3.75K dnia 2014-01-01
Historia cen akcji firmy Eiger BioPharmaceuticals, Inc. od 2014 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2025 -31.11%
2024 -68.15%
2023 -86.27%
2022 -65.86%
2021 -43.34%
2020 -27.82%
2019 28.55%
2018 -15.78%
2017 8.44%
2016 -45.90%
2015 -91.44%
2014 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE